MorphoSys AG logo
MorphoSys AG MOR
report update icon

Quarterly report 2023-Q4
added 07-04-2026

MorphoSys AG Income Statement 2023-2011 | MOR

Brief overview of revenue and earnings at MorphoSys AG

The figures are compared over a five-year interval. According to figures from MorphoSys AG, revenue changed from 76.4 million euros to 238 million euros over five years. Across the full period, sales moved by +211.7%; the average annual rate was 25.5%. The company expanded its revenue base at a high speed.

Gross profit changed from 74.6 million euros to 180 million euros (+141%). At the margin level, the figure shifted from 97.6% to 75.5%. The contraction points to pressure from direct costs or weaker pricing power.

EBITDA was −59.1 million euros at the beginning and 0 euros at the end of the period (+100%). Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −77.3% to 0%. The company improved its ability to convert sales into EBITDA.

What the figures show

The results present an uneven picture without one dominant signal. The constructive conclusion rests on sales growth and positive operating leverage. The overall view is constrained by pressure from direct costs and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement MorphoSys AG

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

624 M 260 M 315 M 922 M 1.13 B 793 M - - - - - - -

Shares

34.3 M 34.2 M 33.4 M 32.5 M 31.6 M 31.3 M 28.9 M 26.4 M - - - - -

Historical Prices

18.2 7.61 9.42 28.3 35.7 25.3 - - - - - - -

Net Income

-190 M -151 M -514 M 97.9 M -103 M -56.2 M -69.8 M -60.4 M 14.9 M -3.01 M 13.3 M 1.94 M 8.22 M

Revenue

238 M 278 M 180 M 328 M 71.8 M 76.4 M 66.8 M 49.7 M 106 M 64 M 78 M 51.9 M 101 M

Cost of Revenue

58.4 M 48.6 M 32.2 M 9.17 M 12.1 M 1.8 M - - - - - - -

Gross Profit

180 M 230 M 147 M 319 M 59.7 M - - 49.6 M 106 M 63.9 M 77.9 M 51.9 M 93.8 M

Operating Income

-252 M -221 M -508 M 18 M -108 M -59.1 M -67.6 M -59.9 M - - - - -

Interest Expense

4.66 M 2.75 M 2.42 M 1.02 M 91 K - - - - - - - -

EBITDA

-252 M -221 M -508 M 18 M -108 M -59.1 M -67.6 M -59.9 M 13.9 M -4.97 M 12.1 M 8.73 M 18.8 M

Operating Expenses

432 M 450 M 656 M 301 M 168 M 137 M 134 M 110 M 93.4 M 69.8 M 68 M 49.5 M 81.6 M

General and Administrative Expenses

65.8 M 60.1 M 78.3 M 51.4 M 36.7 M 21.9 M 15.7 M 13.4 M 10.4 M 9.61 M 11.3 M 12.1 M 24.6 M

All numbers in EUR currency

Quarterly Income Statement MorphoSys AG

2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

34.3 M 34.2 M - - - 33.4 M - - - 32.5 M - - - 31.6 M - - - 31.3 M - - - 28.9 M - - - 26.4 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-190 M -151 M - - - -514 M - - - 97.9 M - - - -103 M - - - -56.2 M - - - -69.8 M - - - -60.4 M - - - - - - - - - - - - - - - - - - - - - - -

Revenue

238 M 278 M - - - 180 M - - - 328 M - - - 71.8 M - - - 76.4 M - - - 66.8 M - - - 49.7 M - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

58.4 M 48.6 M - - - 32.2 M - - - 9.17 M - - - 12.1 M - - - 1.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

180 M 230 M - - - 147 M - - - 319 M - - - 59.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-252 M -221 M - - - -508 M - - - 18 M - - - -108 M - - - -59.1 M - - - -67.6 M - - - -59.9 M - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

4.66 M 2.75 M - - - 2.42 M - - - 1.02 M - - - 91 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-252 M -221 M - - - -508 M - - - 18 M - - - -108 M - - - -59.1 M - - - -67.6 M - - - -59.9 M - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

432 M 450 M - - - 656 M - - - 301 M - - - 168 M - - - 137 M - - - 134 M - - - 110 M - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

65.8 M 60.1 M - - - 78.3 M - - - 51.4 M - - - 36.7 M - - - 21.9 M - - - 15.7 M - - - 13.4 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company MorphoSys AG (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA